Loading...

PE anti-mouse CD86 Antibody

Pricing & Availability
Clone
GL-1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-2, B70, Ly-58
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
GL-1
LPS (3-day) stimulated BALB/c mouse splenocytes stained with GL-1 PE
  • GL-1
    LPS (3-day) stimulated BALB/c mouse splenocytes stained with GL-1 PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
105007 50 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
105008 200 µg 235€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD86 is an 80 kD immunoglobulin superfamily member also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. CD86, along with CD80, is a ligand of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
LPS-activated CBA/Ca mouse splenic B cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The GL-1 antibody can block the mixed lymphocyte reaction in vitro and has been shown to inhibit the priming of cytotoxic T lymphocytes in vivo (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of acetone-fixed frozen sections2,6, immunofluorescence microscopy, and in vivo and in vitro blocking of T cell responses1-6. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 105051-105056).

Application References

(PubMed link indicates BioLegend citation)
  1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
  2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
  5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
  6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed
  11. de Verteuil DA, et al. 2014. J Immunol. 193:1121. PubMed
Product Citations
  1. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  2. Ye Y, et al. 2017. Sci Immunol. 2:17. PubMed
  3. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  4. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  5. Zhang Y, et al. 2018. Sci Rep. 8:5994. PubMed
  6. Sun T, et al. 2018. Front Immunol. 9:1245. PubMed
  7. Jiang H, et al. 2018. Front Pharmacol. 9:612. PubMed
  8. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  9. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  10. Kimura A, et al. 2018. J Exp Med. 215:2197. PubMed
  11. Bell CC, et al. 2019. Nat Commun. 10:2723. PubMed
  12. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  13. Grabinger T, et al. 2019. Front Microbiol. 10:1385. PubMed
  14. Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
  15. Varol D et al. 2017. Immunity. 46(6):1030-1044 . PubMed
  16. Kramer K, et al. 2017. ACS Omega. 0.240972222. PubMed
  17. Gupta P, et al. 2019. Neoplasia. 0.976388889. PubMed
  18. Yuan C, et al. 2020. Braz J Med Biol Res. 53:e9488. PubMed
  19. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  20. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  21. Wang S, et al. 2018. Biomaterials. 187:28:00. PubMed
  22. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  23. Xie Y, et al. 2020. Journal of Neurochemistry. 152(3):368-380.. PubMed
  24. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  25. Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed
  26. Lauterbach MA, et al. 2020. Immunity. 51(6):997-1011.e7.. PubMed
  27. Shih F, et al. 2006. J Immunol. 176:3438. PubMed
  28. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  29. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  30. Škrnjug I, et al. 2014. PLoS One. 9:110150. PubMed
  31. Moreau J, et al. 2015. Blood. 126: 1184-1192. PubMed
  32. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  33. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  34. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  35. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  36. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed
  37. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  38. Utley A, et al. 2020. Cell Rep. 31:107815. PubMed
  39. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  40. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  41. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  42. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  43. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  44. Jin R, et al. 2020. Mol Cancer Ther. . PubMed
  45. Song M, et al. 2021. J Immunol Res. 6696606:2021. PubMed
  46. Fan Q, et al. 2021. Bioact Mater. 6:4014. PubMed
  47. Wang D, et al. 2021. Nan Fang Yi Ke Da Xue Xue Bao. 41:775. PubMed
  48. Saito S, et al. 2020. Nutrients. 12:. PubMed
  49. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  50. Venter C, et al. 2021. Physiol Rep. 9:e14704. PubMed
  51. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  52. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  53. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  54. Reddi RN, et al. 2021. J Am Chem Soc. 143:4979. PubMed
  55. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  56. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  57. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  58. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  59. El-Hindi K, et al. 2022. Int J Mol Sci. 23:. PubMed
  60. Wu Q, et al. 2022. Cell Mol Life Sci. 79:137. PubMed
  61. Jiang H, et al. 2022. Cell Death Dis. 13:183. PubMed
  62. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  63. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  64. Li H, et al. 2022. iScience. 25:104481. PubMed
  65. Zhou Y, et al. 2020. Front Pharmacol. 10:1579. PubMed
  66. Li Y, et al. 2020. Theranostics. 10:2897. PubMed
  67. Song S, et al. 2021. Front Immunol. 12:705140. PubMed
  68. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  69. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  70. Guo D, et al. 2022. Bone Res. 10:45. PubMed
  71. Chen F, et al. 2022. Evid Based Complement Alternat Med. 2022:1240242. PubMed
  72. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  73. Liu C, et al. 2022. Regen Ther. 21:192. PubMed
  74. Wang Y, et al. 2022. Cell Death Dis. 13:748. PubMed
  75. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  76. Jiang W, et al. 2021. J Cell Physiol. 236:7711. PubMed
  77. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  78. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  79. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  80. Liang F, et al. 2021. RSC Adv. 11:35331. PubMed
  81. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  82. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  83. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  84. Tomimatsu M, et al. 2022. Sci Rep. 12:16656. PubMed
  85. Kitagawa S, et al. 2022. NPJ Vaccines. 7:115. PubMed
  86. Tran NL, et al. 2022. Elife. 11:. PubMed
  87. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  88. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  89. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  90. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  91. Pan L, et al. 2022. Mol Immunol. 147:101. PubMed
  92. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  93. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  94. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  95. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  96. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  97. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  98. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  99. Ye Z, et al. 2023. Front Med (Lausanne). 9:1075465. PubMed
  100. Grenov A, et al. 2022. Cell Rep. 39:110778. PubMed
  101. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  102. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  103. Li T, et al. 2023. Adv Sci (Weinh). 10:e2206517. PubMed
  104. Sheng Y, et al. 2023. Cancers (Basel). 15:. PubMed
  105. Solier S, et al. 2023. Nature. 617:386. PubMed
  106. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  107. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  108. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
RRID
AB_313150 (BioLegend Cat. No. 105007)
AB_313151 (BioLegend Cat. No. 105008)

Antigen Details

Structure
Ig superfamily, 80 kD
Distribution

B cells and T cells (upregulated upon activation), macrophages, dendritic cells, and astrocytes

Function
T cell costimulation, Ig class-switching, NK cell cytotoxicity
Ligand/Receptor
CD28, CD152 (CTLA-4)
Cell Type
Astrocytes, B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Hathcock KS, et al. 1993. Science 262:905.
3. Freeman GJ, et al. 1993. Science 262:907.
4. Carreno BM, et al. 2002. Annu. Rev. Immunol. 20:29.

Gene ID
12524 View all products for this Gene ID
UniProt
View information about CD86 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11.30.2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account